Inspira Technologies Oxy B.H.N. Ltd. (IINNW) Aandelenanalyse

Bedrijfsoverzicht

Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company dedicated to the research, development, manufacturing, and marketing of proprietary life support technologies specifically designed for the treatment of acute respiratory failure within the Israeli market. The enterprise operates in the medical technology sector, focusing on the creation of critical care equipment such as the INSPIRA ART100, a life support system utilized in procedural contexts. Despite its specialized operational focus, the company currently reports a market capitalization of N/A and an annual revenue of $289,000, supported by an employee base of 34 individuals. The absence of a disclosed market cap figure alongside the relatively modest revenue of $289,000 suggests that the company operates on a micro-cap scale, indicating it is a smaller entity within the broader financial ecosystem rather than a large-cap industrial player. This limited scale and lack of valuation data imply that the company remains in a stage where market capitalization metrics have not yet been fully established or reported, which often characterizes early-stage or niche medical device firms focusing on specific therapeutic applications.

Financiële gezondheid

The company reported a total revenue of $289,000 over the trailing twelve months, while simultaneously recording a net income of $-13,220,000 and an EBITDA of $-13,473,000. The significant divergence between the revenue figure of $289,000 and the net loss of $-13,220,000 reveals a highly aggressive cost structure or substantial one-time expenses that far outweigh the top-line income generation capabilities of the business. Free cash flow stands at $-5,668,375, which indicates that the company is burning cash at a rapid rate and possesses limited financial flexibility to fund operations without external capital injection or financing. Gross margin is recorded at 0.7%, reflecting that for every dollar of sales, only 0.7 cents remain after direct production costs, signaling a challenging pricing environment or high cost of goods sold. Operating margin is listed at -4713.8% and profit margin at 0.0%, figures that suggest operational losses are so severe relative to sales that they result in negative percentages exceeding the sales base, while the zero profit margin confirms that the company is unable to generate any net earnings from its core activities. On the balance sheet, the company holds $3.16M in cash against $480,000 in debt, resulting in a debt-to-equity ratio of 20.66. Although the company holds significantly more liquid assets than debt obligations, the high debt-to-equity ratio indicates a leveraged position relative to shareholder equity, suggesting that equity capital is a smaller base supporting the existing obligations. The current ratio is 1.56, which indicates that the company has sufficient short-term assets to cover its short-term liabilities, suggesting a conservative approach to immediate liquidity management despite the overall financial losses. Return on equity is -397.9% and return on assets is -127.0%, metrics that reveal that management effectiveness in generating returns is currently negative, meaning the company is destroying value relative to both the capital invested by shareholders and the total assets employed in the business.

Waarderingsbeoordeling

The trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that standard earnings-based valuation multiples cannot be calculated due to the absence of positive earnings, preventing any meaningful comparison of expected earnings trajectory through these specific metrics. The price-to-book ratio is 1.54, indicating that the market values the company's equity at 1.54 times its book value, suggesting a premium over the accounting value of its net assets despite the company's profitability challenges. The price-to-sales ratio and EV/EBITDA are both N/A, which means that alternative valuation metrics relying on sales multiples or enterprise value relative to earnings cannot be utilized to assess the company's intrinsic value or relative standing against peers. The 52-week high is $0.80 and the 52-week low is $0.05, providing a trading range of $0.75 within which the stock has fluctuated. Without a specific current price provided in the available facts to calculate a precise percentage, the stock's position within this range remains undefined by the data, but the wide spread between $0.05 and $0.80 highlights the significant volatility inherent in low-priced securities. The beta value is 2.33, which signifies that the stock price is highly volatile relative to the broader market, moving more than twice as much as the market index on average during periods of fluctuation.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue, as the historical data required to calculate these growth rates is not available in the current reporting period. Since the company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of N/A, it does not distribute earnings to shareholders. Instead, the company reinvests its earnings, or rather its retained cash reserves of $3.16M, into growth initiatives rather than paying dividends to investors. The overall growth and income profile is characterized by a lack of historical growth data, a complete absence of dividend income, and a reliance on cash reserves rather than earnings generation to support future expansion or shareholder returns.